Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack

Prostate

Volumn 62, Issue 2, 2005, Pages 105-114

  Babiker, Adil A ^a,b   Nilsson, Bo ^a   Ronquist, Gunnar ^b   Carlsson, Lena ^b   Ekdahl, Kristina Nilsson ^a,b,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LINNAEUS UNIVERSITY   (Sweden)

Author keywords

CD59; Complement; DU145; LNCaP; PC 3; Prostasomes; Prostate cancer

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; GLYCOSYLPHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DOT HYBRIDIZATION; EPITHELIUM CELL; ERYTHROCYTE; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTASOME; PROSTATE CANCER; PROTEIN CONTENT; RABBIT; SECRETORY GRANULE; SEMINAL PLASMA;

ANIMALS; ANTIBODIES; ANTIGENS, CD59; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; ERYTHROCYTES; FLOW CYTOMETRY; HEMOLYSIS; HUMANS; MALE; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PROSTATIC NEOPLASMS; RABBITS; SECRETORY VESICLES; SEMEN;

EID: 11844299719     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20102     Document Type: Article

References (36)

1. Sugita Y, Nakano Y, Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem (Tokyo) 1988;104(4):633-637.
2. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990;71(1):1-9.
3. Ronquist G, Brody I. The prostasome: Its secretion and function in man. Biochim Biophys Acta 1985;822(2):203-218.
4. Arienti G, Carlini E, Palmerini CA. Fusion of human sperm to prostasomes at acidic pH. J Membr Biol 1997;155(1):89-94.
5. Ronquist G, Nilsson BO, Hjerten S. Interaction between prostasomes and spermatozoa from human semen. Arch Androl 1990;24(2):147-157.
6. Carlsson L, Pahlson C, Bergquist M, Ronquist G, Stridsberg M. Antibacterial activity of human prostasomes. Prostate 2000;44(4):279-286.
7. Skibinski G, Kelly RW, Harkiss D, James K. Immunosuppression by human seminal plasma-extracellular organelles (prostasomes) modulate activity of phagocytic cells. Am J Reprod Immunol 1992;28(2):97-103.
8. Rooney IA, Heuser JE, Atkinson JP. GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells. J Clin Invest 1996;97(7):1675-1686.
9. Kelly RW. Seminal plasma immunosuppressive activity: The achilles heel of reproduction. Int J Androl 1991;14(4):243-247.
10. Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE, Morgan BP. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med 1993;177(5):1409-1420.
11. Kelly RW. Immunosuppressive mechanisms in semen: Implications for contraception. Hum Reprod 1995;10(7):1686-1693.
12. Babiker AA, Ronquist G, Nilsson UR, Nilsson B. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis. Am J Reprod Immunol 2002;47(3):183-192.
13. Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M, Imai Y. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994;73(11):2808-2817.
14. Pangburn MK. Activation of complement via the alternative pathway. Fed Proc 1983;42(1):139-143.
15. Hakulinen J, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 1994;71(6):820-827.
16. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases, and sialic acid. Clin Exp Immunol 2003;131(2):254-263.
17. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M. Complement resistance of tumor cells: Basal and induced mechanisms. Mol Immunol 1999;36 (13-14):929-939.
18. Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 1997;71(6):1049-1055.
19. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999;20(12):576-582.
20. Inoue T, Yamakawa M, Takahashi T. Expression of complement regulating factors in gastric cancer cells. Mol Pathol 2002;55(3): 193-199.
21. Hofman P, Hsi BL, Manie S, Fenichel P, Thyss A, Rossi B. High expression of the antigen recognized by the monoclonal anti-body GB24 on human breast carcinomas: A preventive mechanism of malignant tumor cells against complement attack? Breast Cancer Res Treat 1994;32(2):213-219.
22. Koretz K, Bruderlein S, Henne C, Moller P. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas, and carcinomas. Br J Cancer 1992;66(5):810-814.
23. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement- regulatory proteins in ovarian malignancies. Int J Cancer 1997;70(1):14-25.
24. Gazouli M, Kokotas S, Zoumpourlis V, Zacharatos P, Mariatos G, Kletsas D, Pernnovic B, Athanasiou A, Kittas C, Gorgoulis V. The complement inhibitor CD59 and the lymphocyte function-associated antigen-3 (LFA-3, CD58) genes possess functional binding sites for the p53 tumor suppressor protein. Anticancer Res 2002;22(6C):4237-4241.
25. Carlsson L, Nilsson O, Larsson A, Stridsberg M, Sahlen G, Ronquist G. Characteristics of human prostasomes isolated from three different sources. Prostate 2003;54(4):322-330.
26. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21(3):274-281.
27. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17(1):16-23.
28. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
29. Ronquist G, Frithz G, Jansson A. Prostasome membrane associated enzyme activities and semen parameters in men attending an infertility clinic. Urol Int 1988;43(3):133-138.
30. Nilsson BO, Lennartsson L, Carlsson L, Nilsson S, Ronquist G. Expression of prostasome-like granules by the prostate cancer cell lines PC3, Du145, and LnCaP grown in monolayer. Ups J Med Sci 1999;104(3):199-206.
31. Nilsson UR, Nilsson B. Simplified assays of hemolytic activity of the classical and alternative complement pathways. J Immunol Methods 1984;72(1):49-59.
32. Lindahl M, Tagesson C, Ronquist G. Phospholipase A2 activity in prostasomes from human seminal plasma. Urol Int 1987;42:385-389.
33. Wang J, Lundquist M, Carlsson L, Nilsson O, Lundkvist Ö, Ronquist G. Prostasome-like granules from the PC-3 prostate cancer cell line increase the motility of washed human spermatozoa and adhere to the sperm. Eur J Obstet Gynecol Reprod Biol 2001;96:88-97.
34. Stegmayr B, Brody I, Ronquist G. A biochemical and ultrastructural study on the endogenous protein kinase activity of secretory granule membranes of prostatic origin in human seminal plasma. J Ultrastruct Res 1982;78:206-214.
35. Sahlén G, Ahlander A, Ronquist G, Norlén BJ, Nilsson O. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004 (in press).
36. Ek P, Malm J, Lilja H, Carlsson L, Ronquist G. Exogenous protein kinases A and C, but not endogenous prostasome-associated protein kinase, phosphorylate semenogelins I and II from human semen. J Androl 2002;23(6):806-814.